These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 19757870)

  • 1. Utilities of the EQ-5D: transferable or not?
    Knies S; Evers SM; Candel MJ; Severens JL; Ament AJ
    Pharmacoeconomics; 2009; 27(9):767-79. PubMed ID: 19757870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Comparison of PROPr and EQ-5D-5L Value Sets.
    Pan T; Mulhern B; Viney R; Norman R; Hanmer J; Devlin N
    Pharmacoeconomics; 2022 Mar; 40(3):297-307. PubMed ID: 34786591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjustment of foreign EQ-5D-3L utilities can increase their transferability.
    Oddershede L; Petersen KD
    Clinicoecon Outcomes Res; 2015; 7():629-36. PubMed ID: 26719715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methodological similarities and variations among EQ-5D-5L value set studies: a systematic review.
    Poudel N; Fahim SM; Qian J; Garza K; Chaiyakunapruk N; Ngorsuraches S
    J Med Econ; 2022; 25(1):571-582. PubMed ID: 35416095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of different valuation methods for population health status measured by the EQ-5D in three European countries.
    Bernert S; Fernández A; Haro JM; König HH; Alonso J; Vilagut G; Sevilla-Dedieu C; de Graaf R; Matschinger H; Heider D; Angermeyer MC;
    Value Health; 2009; 12(5):750-8. PubMed ID: 19490564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantifying Parameter Uncertainty in EQ-5D-3L Value Sets and Its Impact on Studies That Use the EQ-5D-3L to Measure Health Utility: A Bayesian Approach.
    Pullenayegum EM; Chan KK; Xie F
    Med Decis Making; 2016 Feb; 36(2):223-33. PubMed ID: 26139449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In search of a 'pan-European value set'; application for EQ-5D-3L.
    Sajjad A; Versteegh MM; Santi I; Busschbach J; Simon J; Roijen LH
    BMC Med Res Methodol; 2023 Jan; 23(1):13. PubMed ID: 36635625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary.
    Rencz F; Brodszky V; Gulácsi L; Golicki D; Ruzsa G; Pickard AS; Law EH; Péntek M
    Value Health; 2020 Sep; 23(9):1235-1245. PubMed ID: 32940242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cultural Values: Can They Explain Differences in Health Utilities between Countries?
    Roudijk B; Donders ART; Stalmeier PFM;
    Med Decis Making; 2019 Jul; 39(5):605-616. PubMed ID: 31257997
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter?
    Yang F; Devlin N; Luo N
    Value Health; 2019 Jan; 22(1):45-49. PubMed ID: 30661633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bayesian Models with Spatial Correlation Improve the Precision of EQ-5D-5L Value Sets.
    Che M; Xie F; Thomas S; Pullenayegum E
    Med Decis Making; 2023 Jul; 43(5):587-594. PubMed ID: 37243474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder.
    Desroziers K; Aballéa S; Maman K; Nazir J; Odeyemi I; Hakimi Z
    Health Qual Life Outcomes; 2013 Nov; 11():200. PubMed ID: 24246044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3125 steps to perfect health: a nonparametric approach to developing the EQ-5D-5L value set.
    Thomas S; Johnson JA; Xie F
    Qual Life Res; 2020 Nov; 29(11):3109-3118. PubMed ID: 32705459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using the EuroQol EQ-5D in Swiss cancer patients, which value set should be applied?
    Matter-Walstra K; Klingbiel D; Szucs T; Pestalozzi BC; Schwenkglenks M
    Pharmacoeconomics; 2014 Jun; 32(6):591-9. PubMed ID: 24671924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of transformation of negative values and regression models on differences between the UK and US EQ-5D time trade-off value sets.
    Augestad LA; Rand-Hendriksen K; Kristiansen IS; Stavem K
    Pharmacoeconomics; 2012 Dec; 30(12):1203-14. PubMed ID: 23116290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International Valuation Protocol for the EQ-5D-Y-3L.
    Ramos-Goñi JM; Oppe M; Stolk E; Shah K; Kreimeier S; Rivero-Arias O; Devlin N
    Pharmacoeconomics; 2020 Jul; 38(7):653-663. PubMed ID: 32297224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing the EQ-5D-5L crosswalks and value sets for England, the Netherlands and Spain: Exploring their impact on cost-utility results.
    Ben Â; Finch AP; van Dongen JM; de Wit M; van Dijk SEM; Snoek FJ; Adriaanse MC; van Tulder MW; Bosmans JE
    Health Econ; 2020 May; 29(5):640-651. PubMed ID: 32059078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valuation of the EQ-5D-3L in Russia.
    Omelyanovskiy V; Musina N; Ratushnyak S; Bezdenezhnykh T; Fediaeva V; Roudijk B; Purba FD
    Qual Life Res; 2021 Jul; 30(7):1997-2007. PubMed ID: 33713323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valuing EQ-5D-Y: the current state of play.
    Devlin N; Pan T; Kreimeier S; Verstraete J; Stolk E; Rand K; Herdman M
    Health Qual Life Outcomes; 2022 Jul; 20(1):105. PubMed ID: 35794607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing EQ-5D valuation studies: a systematic review and methodological reporting checklist.
    Xie F; Gaebel K; Perampaladas K; Doble B; Pullenayegum E
    Med Decis Making; 2014 Jan; 34(1):8-20. PubMed ID: 23525701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.